As the Cell & Gene Therapy (CGT) industry matures, the DACH region is emerging as a critical hub for commercial manufacturing and global supply.
Yet, the road from clinical promise to large-scale delivery remains paved with technical, regulatory, and supply chain challenges — particularly in viral vector capacity, closed-system adoption, and digital factory readiness.
CGT Manufacturing DACH 2026 will unite leaders from biopharma, biotech, CDMOs, regulators, and technology innovators to exchange practical solutions for scaling production, maintaining quality, and enabling global distribution.
CGT Manufacturing DACH is designed for a highly targeted senior audience in the DACH region’s cell & gene therapy ecosystem — leaders in MSAT, quality, regulatory, and supply chain driving advances in viral vectors, allogeneic therapies, in vivo delivery, automated platforms, and digitalized GMP production.
CGT Manufacturing DACH is a focused two-day conference dedicated to solving the region’s most critical cell & gene therapy manufacturing challenges. Through high-level case studies, technical deep dives, and interactive discussions, the event tackles viral vector bottlenecks, closed and automated processing, intensified purification, quality compliance, and digital transformation—equipping attendees with practical strategies to accelerate scale-up and commercialization.
CGT Manufacturing DACH stands out with its exclusive focus on the DACH region’s real-world manufacturing challenges in cell & gene therapy. Tailored for senior leaders across operations, MSAT, QA/QC, and supply chain, it delivers practical, region-specific solutions in an intimate, high-level setting—cutting through the noise of broader CGT events.
Key Themes & Topics
At the heart of CGT Manufacturing DACH, the programme addresses commercial scale-up, manufacturing innovation, and regulatory excellence in advanced therapies:
Industry Roundtables: The Future of CGT Bioprocessing
Interactive discussions with senior leaders on upcoming trends, regional opportunities, and global competitiveness in cell & gene therapy manufacturing.
Overcoming Bottlenecks in Viral Vector Production
Strategies to improve yields, streamline upstream and downstream processes, and manage facility constraints for scalable viral vector supply.
Quality Assurance & Regulatory Compliance in CGT
Addressing GMP, QC, and evolving regulatory requirements for both clinical-stage and commercial-scale manufacturing.
Novel Purification & Intensification Strategies
Exploring next-generation purification platforms, continuous processing, and intensified manufacturing for improved efficiency and throughput.
Manufacturing Innovations for Allogeneic & In Vivo Therapies
Adapting production systems for diverse therapy types, from donor-derived cell therapies to in vivo delivery platforms.
Smart Factories: Digitalization & AI in CGT
Leveraging Digital Twins, automation, and AI to enable predictive, data-driven manufacturing and faster process optimization.
200 max
Senior Attendees
Join the exclusive and focused gathering that unites the DACH region’s cell & gene therapy manufacturing leaders. Connect with senior decision-makers driving the scale-up, compliance, and commercialization of advanced therapies, from viral vector production to allogeneic and in vivo platforms.
30+
Expert Speakers
Gain first-hand insights from industry pioneers on overcoming manufacturing bottlenecks, optimizing closed and automated systems, intensifying production, and ensuring GMP compliance. Learn from real-world case studies shaping the future of CGT manufacturing in DACH and beyond.
20+
Companies Represented
Engage in targeted networking sessions to exchange expertise, discuss regulatory and operational challenges, and explore partnership opportunities with peers, CDMOs, and technology innovators in advanced therapies.
